This lawsuit highlights a critical clinical blind spot: kratom products are widely sold alongside CBD in retail settings, creating confusion about safety profiles and addiction potential. Many patients and clinicians incorrectly assume kratom carries similar low-risk characteristics as CBD, when kratom actually has significant addiction liability through opioid receptor activity.
A New Jersey man has filed suit against CBD Kratom retail stores alleging addiction to kratom beverages. Kratom (Mitragyna speciosa) contains mitragynine and 7-hydroxymitragynine, which act as partial opioid receptor agonists and can produce both euphoric effects and physical dependence. Unlike CBD, which has minimal addiction potential, kratom has well-documented withdrawal syndromes and addiction patterns similar to other opioids. The co-marketing of these botanicals in retail settings creates patient confusion about their distinct pharmacological profiles.
“I see patients regularly who don’t realize kratom and CBD are completely different substances with vastly different addiction risks. This case underscores why I always ask specifically about kratom use — it’s not ‘herbal CBD,’ it’s an opioid-acting substance that requires the same addiction risk assessment as any opioid.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is kratom and how does it relate to opioid addiction?
Kratom is a plant-based substance that has been used by some individuals as an alternative to opioids for pain management and addiction recovery. The substance contains compounds that can interact with opioid receptors in the brain, potentially offering benefits for those seeking to reduce opioid dependence.
Is kratom legally available in retail cannabis dispensaries?
Kratom’s legal status varies by jurisdiction and it is not universally available in cannabis retail outlets. Some states and localities have banned kratom, while others allow its sale in specialized stores or dispensaries, depending on local regulations.
What are the potential risks associated with kratom use?
Kratom can cause side effects including nausea, constipation, and drowsiness, and may have potential for dependence with regular use. The FDA has raised concerns about kratom’s safety profile and potential for abuse, particularly when used in high doses or combined with other substances.
How does kratom compare to traditional opioid addiction treatments?
While some users report kratom helps with opioid withdrawal symptoms, it is not an FDA-approved treatment for opioid addiction. Traditional evidence-based treatments like methadone, buprenorphine, and naltrexone remain the gold standard for opioid use disorder treatment with established safety and efficacy profiles.
Why is this topic considered clinically relevant for healthcare providers?
Healthcare providers need to be aware of kratom use among patients as it may interact with other medications and affect treatment plans. Understanding patient use of kratom is important for comprehensive addiction treatment and monitoring potential complications or benefits in clinical practice.
